Literature DB >> 24325545

Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30.

Gemma Cramarossa1, Liang Zeng, Liying Zhang, Ling-Ming Tseng, Ming-Feng Hou, Alysa Fairchild, Vassilios Vassiliou, Reynaldo Jesus-Garcia, Mohamed A Alm El-Din, Aswin Kumar, Fabien Forges, Wei-Chu Chie, Arjun Sahgal, Henry Lam, Natalie Pulenzas, Edward Chow.   

Abstract

OBJECTIVE: To identify which domains/symptoms from the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were predictive of overall quality of life (QoL) in advanced cancer patients.
METHODS: Four hundred and forty seven patients with brain metastases or bone metastases from seven countries were enrolled with regression analysis to determine the predictive value of the QLQ-C30 functional/symptom scores for patient reported overall QoL (question 30), overall health (question 29) and the global health status domain (questions 29 and 30).
RESULTS: Worse role functioning, social functioning, fatigue and financial problems were the most significant predictive factors for worse QoL. In the bone metastases subgroup (n = 400), role functioning, fatigue and financial problems were the most significant predictors. In patients with brain metastases (n = 47), none of the EORTC domains significantly predicted worse QOL.
CONCLUSION: Deterioration of certain QLQ-C30 functional/symptom scores significantly contributes to worse QoL, overall health and global health status.

Entities:  

Mesh:

Year:  2013        PMID: 24325545     DOI: 10.1586/14737167.2014.864560

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  2 in total

1.  Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michelle Liu; Carol Stober; Gregory Pond; Mashari Jemaan Alzahrani; Michael Ong; Scott Ernst; Christopher Booth; Mihaela Mates; Anil Abraham Joy; Olexiy Aseyev; Phillip Blanchette; Lisa Vandermeer; Megan Tu; Kednapa Thavorn; Dean Fergusson
Journal:  J Bone Oncol       Date:  2021-09-02       Impact factor: 4.072

2.  A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer.

Authors:  Mark Clemons; Michael Ong; Carol Stober; Scott Ernst; Christopher Booth; Christina Canil; Mihaela Mates; Andrew Robinson; Phillip Blanchette; Anil Abraham Joy; John Hilton; Olexiy Aseyev; Gregory Pond; Ahwon Jeong; Brian Hutton; Sasha Mazzarello; Lisa Vandermeer; Igal Kushnir; Dean Fergusson
Journal:  Eur J Cancer       Date:  2020-10-03       Impact factor: 9.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.